Work

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

Year: 2011

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-011-1667-z

Authors: J. R. Infante, R. Kurzrock, J. Spratlin, H. A. Burris, S. G. Eckhardt, J. Li, K. Wu, J. M. Skolnik, L. Hylander-Gans, A. Osmukhina, D. Huszar, R. S. Herbst

Institutions: Sarah Cannon Research Institute, Sarah Cannon, The University of Texas MD Anderson Cancer Center, University of Colorado Cancer Center, AstraZeneca (United States), Yale Cancer Center, Yale University

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AstraZeneca

OpenAlex ID: W2070336047

FWCI: 3.064

Cites: 27

Cited by: 35

Related to: 10